Japan Medical Dynamic Marketing, The Current Fiscal Year Net Income Revised Downward to a Loss

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Thu Mar 27, 2025 3:30 pm JST Revision

7600 Japan Medical Dynamic Marketing, INC. 【J-GAAP】

Guidance Update Report

Japan Medical Dynamic Marketing, INC. <7600> [TSE Prime] announced a performance revision after the market closed on March 27th (15:30). The consolidated net income/loss for the fiscal year ending March 2025 has been revised downward from an expected profit of 1.3 billion yen to a loss of 0.25 billion yen (compared to a profit of 1.27 billion yen in the previous period), turning to a loss outlook.

Based on the downwardly revised full-year plan announced by the company, our calculation indicates that the October to March period (2H) consolidated net income/loss has been revised downward from an expected profit of 0.8 billion yen to a loss of 0.74 billion yen (compared to a profit of 0.91 billion yen in the same period of the previous year), turning to a loss outlook.

Kabutan News

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024 Prev	13,383	1,181	1,186	804	30.5	15	Oct 30, 2024	J-GAAP
Oct - Mar, 2024 New	13,183	831	796	-746	-28.3	15	Mar 27, 2025	J-GAAP
Revision Rate	-1.5%	-29.6%	-32.9%	－	－

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	25,200	1,850	1,850	1,300	49.4	15	Apr 30, 2024	J-GAAP
Mar, 2025 New	25,000	1,500	1,460	-250	-9.5	15	Mar 27, 2025	J-GAAP
Revision Rate	-0.8%	-18.9%	-21.1%	－	－

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	12,225	1,129	1,210	912	34.7	14	Apr 30, 2024	J-GAAP
Oct - Mar, 2024 Guidance	13,183	831	796	-746	-28.3	15	Mar 27, 2025	J-GAAP
YoY	+7.8%	-26.4%	-34.2%	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	21,307	2,024	2,043	1,423	54.0	13	Apr 28, 2023	J-GAAP
Mar, 2024	23,177	1,746	1,842	1,271	48.3	14	Apr 30, 2024	J-GAAP
Mar, 2025 Guidance	25,000	1,500	1,460	-250	-9.5	15	Mar 27, 2025	J-GAAP
YoY	+7.9%	-14.1%	-20.7%	－	－